https://www.selleckchem.com/pr....oducts/Temsirolimus.
06 per year, 95%CI =1.03-1.1 compared to TT, even for prolonged (3weeks) MV (38.1%). Higher risk-adjusted mortality was associated with longer duration of MV and after 9days of MV with retention of ETT compared with TT - average (mortality) treatment effect 12.6% (95%CI =10.7-14.5). The latter was not significant after 30days of MV. The safety of ETT compared with TT beyond short-term MV (≤9-days) is uncertain and requires prospective evaluation with additional data. The safety of ETT compared with TT beyond short-term MV (≤9
Like
Comment
Share
